Table 1 Main characteristics of the eligible studies
First author | Year | country | Study type | Participations(n) (HER2-low/ HER2-zero) | Clinical stage | Follow-up (median) (month) | HR estimation | Outcomes (All) | Outcomes (HR+) | Outcomes(HR-) |
|---|---|---|---|---|---|---|---|---|---|---|
Denkert | 2021 | Germany | retrospective | 2310 (1098/1212) | I–III | 46.6 | Given by author | OS, DFS | OS, DFS | OS, DFS |
de Moura | 2021 | South America | retrospective | 855 (285/570) | I–III | 59 | Survival curve | OS | OS | OS |
Domergue | 2022 | France | retrospective | 437 (121/316) | I–III | 72.9 | Survival curve | NR | NR | OS, DFS |
Alves | 2022 | Portugal | retrospective | 72 (41/31) | II–III | 35.5 | Survival curve | OS, DFS | NR | NR |
Cosimo | 2022 | Italy | retrospective | 444 (335/109) | I–III | 59.6 | Survival curve | DFS | DFS | DFS |
Shao | 2022 | China | retrospective | 314 (226/88) | II–III | 36 | Survival curve | OS, DFS | OS, DFS | OS, DFS |
Kang | 2022 | Korea | retrospective | 1572 (754/818) | I–III | NR | Given by author | OS, DFS | OS, DFS | OS, DFS |
Zhou | 2023 | China | retrospective | 325 (234/91) | I–III | 29.3 | Given by author | OS, DFS | NR | NR |
Qiao | 2023 | China | retrospective | 132 (70/62) | II–III | 20 | Survival curve | OS, DFS | OS, DFS | OS, DFS |
Li | 2023 | China | retrospective | 1027 (678/349) | I–III | 56 | Survival curve | OS, DFS | OS, DFS | OS, DFS |
Pöschke | 2023 | Germany | retrospective | 1373 (930/443) | I–III | 120 | Survival curve | OS, DFS | OS, DFS | OS, DFS |
Li JJ | 2023 | China | retrospective | 283 (239/44) | II–III | 59 | Survival curve | OS | OS | OS |
Zhong | 2023 | US | retrospective | 41,500 (26,686/14,814) | I–III | NR | Given by author | OS | OS | OS |
Zhang | 2023 | China | retrospective | 3070 (2340/730) | I–III | 40 | Survival curve | NR | OS, DFS | NR |